New Study Aims to Reduce Recurrence Risk for Select Patients
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.
A Year in Review: 2020
Although COVID-19 dominated the news, important new research and clinical trials began for pancreatic cancer patients.
A Second Opinion Makes the Difference
Irma Infante refused to give up after a stage IV pancreatic cancer diagnosis. She went for a second opinion and better treatment options.
Earlier Detection of Pancreatic Cancer: A Marathon, Not A Sprint
Dino Verrelli of Project Purple joins forces with Dr. Diane Simeone on the PRECEDE Consortium to develop earlier detection and new pancreatic cancer treatments.
Decoding the Differences between At-Home and Medical Genetic Testing
Genetic counselors Jill Stopfer and Heather Hampel explain the differences between at-home and medical genetic testing, including precision and knowledge.
Looking Back at the Year in Research: 2019
The research highlights of 2019 include: approval of a PARP inhibitor, artificial intelligence to diagnose pancreatic cysts, and updated radiation guidelines.
The Relationship Between Diabetes and Pancreatic Cancer
Whether you have type 1 or type 2 diabetes you are at an increased risk for developing pancreatic cancer. Learn more about your risk by reading this story.
Questions to Ask Before You Begin Chemotherapy
Do you want to better understand your pancreatic cancer treatment? Dr. Andrew Hendifer outlines important questions to ask before starting chemotherapy.
GENERATE Study Aims to Improve Genetic Testing and Prevention for Pancreatic Cancer
Dr. Sapna Syngal outlines the GENERATE study, which aims to help families with a risk for pancreatic cancer by providing genetic testing.
New NCCN Guidelines Stress Genetic Testing For All Pancreatic Cancer Patients
Dr. Sapna Syngal discusses the new NCCN guidelines, which support genetic testing for all pancreatic cancer patients, because mutations can influence treatment.